Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion

Journal of Clinical Investigation

Volumn 116, Issue 10, 2006, Pages 2748-2756

  Fischer, Marie ^a,b   Harvima, Ilkka T ^c   Carvalho, Ricardo F S ^a   Möller, Christine ^a   Naukkarinen, Anita ^c   Enblad, Gunilla ^b   Nilsson, Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CHEMOKINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; ATOPIC DERMATITIS; DEGRANULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; MAST CELL; ORGAN CULTURE; PRIORITY JOURNAL; PSORIASIS; RECEPTOR UPREGULATION; SKIN DEFECT; SKIN INFLAMMATION;

ADOLESCENT; ADULT; ANTIGENS, CD30; CD30 LIGAND; CELL DEGRANULATION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINES; CYTOKINES; DERMATITIS, ATOPIC; FEMALE; FETAL BLOOD; GENE EXPRESSION; HISTAMINE RELEASE; HUMANS; INTERLEUKIN-8; LEUKOTRIENES; MACROPHAGE INFLAMMATORY PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEINS; MALE; MAP KINASE SIGNALING SYSTEM; MAST CELLS; MIDDLE AGED; PSORIASIS; SKIN DISEASES; TRYPTASES; UP-REGULATION;

EID: 33749432608     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24274     Document Type: Article

References (50)

1. Nathan, C. 2002. Points of control in inflammation. Nature. 420:846-852.
2. Galli, S.J., Maurer, M., and Lantz, C.S. 1999. Mast cells as sentinels of innate immunity. Curr. Opin. Immunol. 11:53-59.
3. Supajatura, V., et al. 2002. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J. Clin. Invest. 109:1351-1359. doi:10.1172/JCI200214704.
4. Marshall, J.S., King, C.A., and McCurdy, J.D. 2003. Mast cell cytokine and chemokine responses to bacterial and viral infection. Curr. Pharm. Des. 9:11-24.
5. Benoist, C., and Mathis, D. 2002. Mast cells in autoimmune disease. Nature. 420:875-878.
6. Lee, D.M., et al. 2002. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 297:1689-1692.
7. Coussens, L.M., and Werb, Z. 2001. Inflammatory cells and cancer: think different! J. Exp. Med. 193:F23-F26.
8. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
9. Molin, D., et al. 2002. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br. J. Haematol. 119:122-124.
10. Smith, C.A., et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 73:1349-1360.
11. Gruss, H.J., et al. 1996. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am. J. Pathol. 149:469-481.
12. Pinto, A., et al. 1996. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood. 88:3299-3305.
13. Molin, D., et al. 2001. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br. J. Haematol. 114:616-623.
14. Schwab, U., et al. 1982. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 299:65-67.
15. Stein, H., et al. 1985. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 66:848-858.
16. Del Prete, G., et al. 1995. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J. Exp. Med. 182:1655-1661.
17. Bengtsson, A., Holm, L., Back, O., Fransson, J., and Scheynius, A. 1997. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin. Exp. Immunol. 109:533-537.
18. Horie, R., and Watanabe, T. 1998. CD30: expression and function in health and disease. Semin. Immunol. 10:457-470.
19. Caproni, M., et al. 1997. In vivo relevance of CD30 in atopic dermatitis. Allergy. 52:1063-1070.
20. Hamann, D., et al. 1996. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J. Immunol. 156:1387-1391.
21. Bengtsson, A., et al. 1995. Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. J. Leukoc. Biol. 58:683-689.
22. Ferenczi, K., Burack, L., Pope, M., Krueger, J.G., and Austin, L.M. 2000. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun. 14:63-78.
23. Ackermann, L., and Harvima, I.T. 1998. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch. Dermatol. Res. 290:353-359.
24. Horsmanheimo, L., et al. 1994. Mast cells are one major source of interleukin-4 in atopic dermatitis. Br. J. Dermatol. 131:348-353.
25. Wiley, S.R., Goodwin, R.G., and Smith, C.A. 1996. Reverse signaling via CD30 ligand. J. Immunol. 157:3635-3639.
26. Cerutti, A., et al. 2000. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J. Immunol. 165:786-794.
27. Saraiva, M., Smith, P., Fallon, P.G., and Alcami, A. 2002. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J. Exp. Med. 196:829-839.
28. Galli, S.J., Nakae, S., and Tsai, M. 2005. Mast cells in the development of adaptive immune response. Nat. Immunol. 6:135-142.
29. Marshall, J.S. 2004. Mast-cell responses to pathogens. Nat. Rev. Immunol. 4:787-799.
30. Mellor, E.A., Austen, K.F., and Boyce, J.A. 2002. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J. Exp. Med. 195:583-592.
31. Secor, V.H., Secor, W.E., Gutekunst, C.A., and Brown, M.A. 2000. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191:813-822.
32. Poppema, S. 1989. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am. J. Pathol. 135:351-357.
33. Higashi, N., Bang, K., Gesser, B., Lund, M., and Thestrup-Pedersen, K. 2001. Cytokine expression of skin T-lymphocytes from patients with atopic dermatitis. Acta Derm. Venereol. 81:3-7.
34. Ackermann, L., et al. 1999. Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br. J. Dermatol. 140:624-633.
35. Uyemura, K., Yamamura, M., Fivenson, D.F., Modlin, R.L., and Nickoloff, B.J. 1993. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 101:701-705.
36. Salamon, P., Shoham, N.G., Gavrieli, R., Wolach, B., and Mekori, Y.A. 2005. Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy. 60:1316-1319.
37. Hansen, H.P., et al. 1995. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int. J. Cancer. 63:750-756.
38. van Essen, D., Kikutani, H., and Gray, D. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature. 378:620-623.
39. Stuber, E., Neurath, M., Calderhead, D., Fell, H.P., and Strober, W. 1995. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity. 2:507-521.
40. Suzuki, I., and Fink, P.J. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J. Exp. Med. 187:123-128.
41. Duan, H., et al. 2001. Interleukin-8-positive neutrophils in psoriasis. J. Dermatol. Sci. 26:119-124.
42. Hatano, Y., Katagiri, K., and Takayasu, S. 1999. Increased levels in vivo of mRNAs for IL-8 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis (AD). Clin. Exp. Immunol. 117:237-243.
43. Jiang, W.Y., Chattedee, A.D., Raychaudhuri, S.P., Raychaudhuri, S.K., and Farber, E.M. 2001. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int. J. Dermatol. 40:699-703.
44. Moser, B., Wolf, M., Walz, A., and Loetscher, P. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25:75-84.
45. Nomura, I., et al. 2003. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J. Allergy Clin. Immunol. 112:1195-1202.
46. Maggio, E., et al. 2002. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann. Oncol. 13(Suppl. 1):52-56.
47. Nilsson, G., et al. 1996. Stem cell factor-dependent human cord blood derived mast cells express alpha- and beta-tryptase, heparin and chondroitin sulphate. Immunology. 88:308-314.
48. Saito, H., et al. 1996. Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J. Immunol. 157:343-350.
49. Harvima, I.T., Naukkarinen, A., Harvima, R.J., and Horsmanheimo, M. 1989. Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. Arch. Dermatol. Res. 281:387-391.
50. Kivinen, P.K., Nilsson, G., Naukkarinen, A., and Harvima, I.T. 2003. Mast cell survival and apoptosis in organ-cultured human skin. Exp. Dermatol. 12:53-60.